Advertisement

Hodentumoren

  • Jörg Thomas Hartmann
  • Markus Kuczyk
  • Carsten Bokemeyer
Part of the Onkologie heute book series (ONKOLOGIE)

Zusammenfassung

Testiculäre Keimzelltumoren gehören zu den Malignomen des Erwachsenen, die selbst im metastasierten Stadium in hohem Maße heilbar sind. Addiert man die Therapieergebnisse für alle Krankheitsstadien, so liegt die Gesamtüberlebensrate nach 5 Jahren bei über 90%.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. [1]
    Ahlgren AD, Simrell CR, Triche TJ, et al. (1984) Sarcoma arising in a residual testicular teratoma after cytoreductive chemotherapy. Cancer 54: 2015–2018.PubMedGoogle Scholar
  2. [2]
    Albers P, Albers J, Cummings OW, et al. (1995) Flow cytometric and cytophotometric DNA analysis cannot predict subsequent tumour recurrence in pathological stage IIA/B non-seminomatous testicular germ cell tumour patients who do not receive adjuvant chemotherapy [letter]. Eur J Cancer 31 A: 848–849.Google Scholar
  3. [3]
    Albers P, Bierhoff E, Neu D, et al. (1997) MIB-1 immunohistochemistry in clinical stage I nonseminomatous testicular germ cell tumors predicts patients at low risk for metastasis. Cancer 79: 1710–1716.PubMedGoogle Scholar
  4. [4]
    Bajorin DF, Motzer RJ, Rodriquez E, et al. (1993a) Acute nonlymphocytic leukemia in germ cell tumor patients treated with etoposide-containing chemotherapy. J Natl Cancer Inst 85: 60–62.PubMedGoogle Scholar
  5. [5]
    Bajorin DF, Sarosdy MF, Pfister DG, et al. (1993b) Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: A multiinstitutional study. J Clin Oncol 11: 598–606.PubMedGoogle Scholar
  6. [6]
    Bamberg M, Schmidberger H, Meisner C, et al. (1999) Radiotherapy for stages I and IIA/B testicular seminoma. Int J Cancer 83(6): 823–827.PubMedGoogle Scholar
  7. [7]
    Baniel J, Foster RS, Gonin R, et al. (1995) Late relapse of testicular cancer. J Clin Oncol 13: 1170–1176.PubMedGoogle Scholar
  8. [8]
    Batata M, Chu F, Hilaris B, et al. (1982) Testicular cancer in cryptorchids. Cancer 49: 1023–1030.PubMedGoogle Scholar
  9. [9]
    Bhatia S, Cornetta K, Broun R, et al. (1998) High dose chemotherapy with peripheral stem cell or autologous bone marrow transplant as initiaal salvage chemotherapy for testicular cancer. Proc Am Soc Clin Oncol 17: 321a (abstr. 1239).Google Scholar
  10. [10]
    Berger CC, Bokemeyer C, Schneider M, et al. (1995) Secondary Raynaud’s phenomenon and other late vascular complications following chemotherapy for testicular cancer. Eur J Cancer 31: 2229–2238.Google Scholar
  11. [11]
    Berger CC, Bokemeyer C, Schuppert F, et al. (1996) Endocrinological late effects after chemotherapy for testicular cancer. Br J Cancer 73: 1108–1114.PubMedGoogle Scholar
  12. [12]
    Beyer J, Kramar A, Mandanas R, et al. (1996) High-dose chemotherapy as salvage treatment in germ cell tumors: A multivariate analysis of prognostic variables. J Clin Oncol 14:2638–2645.PubMedGoogle Scholar
  13. [13]
    Beyer J, Kingreen D, Krause M, et al. (1997) Long-term survival of patients with recurrent or refractory germ cell tumors after high dose chemotherapy. Cancer 79: 161–168.PubMedGoogle Scholar
  14. [14]
    Beyer J, Stenning A, Gerl S, et al. (1999) High-dose versus conventional-dose first-salvage treatment in nonseminoma: A matched-pair analysis. Proc Am Soc Clin Oncol 18:326a(abstr. 1255).Google Scholar
  15. [15]
    Birch R, Williams S, Cone A, et al. (1986) Prognostic factors for favourable outcome in disseminated germ cell tumors. J Clin Oncol 4: 400–407.PubMedGoogle Scholar
  16. [16]
    Blijham G (1981) The treatment of advanced testicular carcinoma with high dose chemotherapy and autologous marrow support. Eur J Cancer Clin Oncol 17: 433–441.Google Scholar
  17. [17]
    Bokemeyer C, Schmoll HJ (1993) Secondary neoplasms following treatment of malignant germ cell tumors. J Clin Oncol 11: 1703–1709.PubMedGoogle Scholar
  18. [18]
    Bokemeyer C, Schmoll HJ, Natt F, et al. (1994) Preliminary results of a phase I/II trial of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer. J Cancer Res Clin Oncol 120: 754–757.PubMedGoogle Scholar
  19. [19]
    Bokemeyer C, Schmoll HJ (1995a) Treatment of testicular cancer and the development of secondary malignancies. J Clin Oncol 13: 283–292.PubMedGoogle Scholar
  20. [20]
    Bokemeyer C, Schmoll HJ, Kuczyk MA, et al. (1995b) Risk of secondary leukemia following high cumulative doses of etoposide during chemotherapy for testicular cancer. J Natl Cancer Inst 87: 58–60.PubMedGoogle Scholar
  21. [21]
    Bokemeyer C, Kuczyk MA, Serth J, et al. (1996a) Treatment of clinical stage I testicular and cancer and the possible role for new biological prognostic parameters. J Clin Oncol Res Clin Oncol 122: 575–584.Google Scholar
  22. [22]
    Bokemeyer C, Köhrmann O, Tischler J, et al. (1996b) A randomized trial of cisplatin, etoposide and bleomycin (PEB) versus carboplatin, etoposide and bleomycin (CEB) for patients with ‘good-risk’ metastatic non-seminomatous germ cell tumours. Ann Oncol 7: 1015–1021.PubMedGoogle Scholar
  23. [23]
    Bokemeyer C, Kuczyk MA, Kohne H, et al. (1996d) Hematopoietic growth factors and treatment of testicular cancer: biological interactions, routine use and dose-intensive chemotherapy. Ann Hematol 72: 1–9.PubMedGoogle Scholar
  24. [24]
    Bokemeyer C, Berger CC, Kuczyk MA, et al. (1996e) Evaluation of long-term toxicity after chemotherapy for testicular cancer. J Clin Oncol 14: 2923–2932.PubMedGoogle Scholar
  25. [25]
    Bokemeyer C, Beyer J, Rüther U, et al. (1996c) Phase II study of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer. Ann Oncol 7: 31–34.PubMedGoogle Scholar
  26. [26]
    Bokemeyer C, Berger CC, Hartmann JT, et al. (1998a) Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer. Br J Cancer 77: 1355–1362.PubMedGoogle Scholar
  27. [27]
    Bokemeyer C, Harstrick A, Beyer C, et al. (1998b) The use of dose-intensified chemotherapy in the treatment of metastatic nonseminomatous testicular germ cell tumors. Semin Oncol 25(suppl. 4): 24–32.PubMedGoogle Scholar
  28. [28]
    Bokemeyer C, Hartmann JT, Kuczyk MA, et al. (1998c) The role of paclitaxel in chemosensitive urological malignancies: Current strategies in bladder cancer and testicular germ-cell tumors. World J Urol 16: 155–162.PubMedGoogle Scholar
  29. [29]
    Bokemeyer C, Gerl A, Schöffski, et al. (1999a) Gemcitabine in patients with relapsed or cisplatin-refractory testicular cancer. J Clin Oncol 17: 512–516.PubMedGoogle Scholar
  30. [30]
    Bokemeyer C, Kollmannsberger C, Meisner C, et al. (1999b) First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: A multivariate and matched-pair analysis. J Clin Oncol. 17(11): 3450–3456.PubMedGoogle Scholar
  31. [31]
    Bokemeyer C, Hartmann JT, Droz JP, et al. (2000) Prognostic factors and outcome of patients with extragonadal germ cell tumors (EGGCT). Proc Am Soc Clin Oncol 19: 328a(abstr. 1288).Google Scholar
  32. [32]
    Bokemeyer C, Droz JP, Horwich A, et al. (2001) Extragonadal seminoma — an international multicenter analysis of prognostic factors and longterm treatment outcome. Cancer (in press).Google Scholar
  33. [33]
    Bosl GJ, Geller LN, Cirricione C, et al. (1983) Multivariate analysis of prognostic variables in patients with metastatic cancer. Cancer Res 43: 3403–3404.PubMedGoogle Scholar
  34. [34]
    Bosl GJ, Yagoda A, Golbey RB, et al. (1985) Role of etoposide-based chemotherapy in the treatment of patients with refractory or relapsing germ cell tumors. Am J Med 78: 423–428.PubMedGoogle Scholar
  35. [35]
    Bosl GJ, Leitner SP, Atlas SA, et al. (1986) Increased plasma renin and aldosterone in patients treated with cisplatin-based chemotherapy for metastatic germ-cell tumors. J Clin Oncol 4: 1684–1689.PubMedGoogle Scholar
  36. [36]
    Bosl GJ, Geller NL, Bajorin D, et al. (1988) A randomized trial of etoposide+cisplatin versus vinblastine+bleomycin+cisplatin+cyclophosphamide+dactinomycin in patients with good-prognosis germ cell tumor. J Clin Oncol 6: 1231–1238.PubMedGoogle Scholar
  37. [37]
    Bosl GJ, Ilson DH, Rodriguez E, et al. (1994) Clinical relevance of the i(12p) marker chromosome in germ cell tumors. J Natl Cancer Inst 86: 349–355.PubMedGoogle Scholar
  38. [38]
    Boyer M, Raghavan D, Harris PJ, et al. (1990) Lack of late toxicity in patients treated with cisplatin-containing combination chemotherapy for metastatic testicular cancer. J Clin Oncol 8: 21–26.PubMedGoogle Scholar
  39. [39]
    Boyer M, Raghavan D (1992) Toxicity of treatment of germ cell tumors. Sem Oncol 2: 128–142.Google Scholar
  40. [40]
    Brenner PC, Harry W, Morse MJ, et al. (1996) Simultaneous retroperitoneal, thoracic, and cervical resection of postchemotherapy residual masses in patients with metastatic nonseminomatous germ cell tumors of the testis. J Clin Oncol 14: 1765–1769.PubMedGoogle Scholar
  41. [41]
    Broun ER, Nichols CR, Kneebone P, et al. (1992) Long-term outcome of patients with relapsed and refractory germ cell tumors treated with high-dose chemotherapy and autologous bone marrow rescue. Ann Intern Med 117: 124–128.PubMedGoogle Scholar
  42. [42]
    Broun ER, Nichols CR, Mandanas R, et al. (1995) Dose escalation study of high-dose carboplatin and etoposide with autologous bone marrow support in patients with recurrent and refractory germ cell tumors. Bone Marrow Transplant 16: 353 358.PubMedGoogle Scholar
  43. [43]
    Buetow SA (1995) Epidemiology of testicular cancer. Epidemiol Rev 17: 433–449.PubMedGoogle Scholar
  44. [44]
    Cavalli F, Monfardini S, Pizzocaro G (1980) Report on the International Workshop on Staging and Treatment of Testicular Cancer. Eur J Cancer 16: 1367–1372.PubMedGoogle Scholar
  45. [45]
    Chaganti RS, Rodriguez E, Bosl GJ (1993) Cytogenetics of male germ cell tumors. Urol Clin North Am 20: 55–66.PubMedGoogle Scholar
  46. [46]
    Chevreau C, Droz JP, Pico JC, et al. (1993) Early intensified chemotherapy with autologous bone marrow transplantation in first line treatment of poor risk non-seminomatous germ cell tumors. Eur Urol 23: 213–218.PubMedGoogle Scholar
  47. [47]
    Clemm C, Gerl A, Hentrich M, et al. (1995) Chemotherapy for far advanced seminoma. Onkologie 18: 189 (abstr. 909).Google Scholar
  48. [48]
    Clemm C, Bokemeyer C, Gerl A, et al. (2000) Randomized trial comparing cisplatin/etoposide/ifosfamide with carboplatin monochemotherapy in patients with advanced metastatic seminoma. Proc Am Soc Clin Oncol 19: 326a (abstr. 1283).Google Scholar
  49. [49]
    Collins DH, Pugh RCB (1964) Classification and frequency of testicular tumours. Br J Urol 36(Suppl.): 1.PubMedGoogle Scholar
  50. [50]
    Coogan CL, Hejase MJ, Wähle GR, et al. (1996) Nerve sparing post-chemotherapy retroperitoneal lymph node dissection for advanced testicular cancer. J Urol 156: 1656–1658.PubMedGoogle Scholar
  51. [51]
    Culine S, Kerbrat P, Bouzy J, et al. (1999) Are 3 cycles of Bleomycin, etoposide and cisplatin (3BEP) or 4 cycles of etoposide and cisplatin (4EP) equivalent regimens for patients (pts) with good-risk metastatic non seminomatous germ cell tumors (NSGCT)? Preliminary results of a randomized trial. Proc Am Soc Clin Oncol 18: 309a (abstr. 1188).Google Scholar
  52. [52]
    Cullen MH, Stenning SP, Parkinson MC, et al. (1996) Short course adjuvant chemotherapy in high risk stage I non-seminomatous germ cell tumours of the testis: A medical research council report. J Clin Oncol 14: 1106–1113.PubMedGoogle Scholar
  53. [53]
    Decatris MP, Wilkinson PM, Welch RS, et al. (2000) High-dose chemotherapy and autologous haematopoietic support in poor risk non-seminomatous germ-cell tumours: An effective first-line therapy with minimal toxicity. Ann Oncol 11: 427–434.PubMedGoogle Scholar
  54. [54]
    de Wit R, Stoter G, Sleijfer DT, et al. (1995) Four cycles of BEP versus an alternating regime of PVB and BEP in patients with poor-prognosis metastatic testicular nonseminoma. A randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group. Br JCancer 71: 1311–1314.Google Scholar
  55. [55]
    de Wit R, Stoter G, Kaye SB, et al. (1997) Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma. A randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. J Clin Oncol 15: 1837–1843.PubMedGoogle Scholar
  56. [56]
    de Wit R, Stoter G, Sleijfer DT, et al. (1998) Four cycles of BEP versus four cycles of VIP in patients with intermediate-prognosis metastatic testicular non-seminoma. A randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group. Br J Cancer 78: 828–832.PubMedGoogle Scholar
  57. [57]
    de Wit R, Louwerens M, de Mulder PH, et al. (1999) Management of intermediate-prognosis germ-cell cancer: Results of a phase I/II study of Taxol-BEP. Int J Cancer 83(6): 831–833.PubMedGoogle Scholar
  58. [58]
    de Wit R, Roberts JT, Wilkinson P, et al. (2000) Final analysis demonstrating the equivalence of 3 BEP vs. 4 cycles and the 5 day schedule vs. 3 days per cycle in good prognosis germ cell cancer. Proc Am Soc Clin Oncol 19: 326a (abstr. 1281).Google Scholar
  59. [59]
    Dieckmann KP, Pichlmeier U (1977) The prevalence of familiar testicular cancer: An analysis of two patient populations and a review of the literature. Cancer 80: 1954–1960.Google Scholar
  60. [60]
    Dieckmann KP, Loy V (1996) Prevalence of contralateral testicular intraepithelial neoplasia in patients with germ cell neoplasia. J Clin Oncol 14: 3126–3132.PubMedGoogle Scholar
  61. [61]
    Donohue JP, Zachary JM, Maynard BR (1982) Distribution of nodal metastases in nonseminomatous testis cancer. J Urol 128: 315–320.PubMedGoogle Scholar
  62. [62]
    Donohue JP, Foster RS, Rowland RG, et al. (1990) Nerve-sparing retroperitoneal lymphadenectomy with preservation of ejaculation. J Urol 144: 287–291.PubMedGoogle Scholar
  63. [63]
    Donohue JP, Thornhill JA, Foster RS, et al. (1993) Primary retroperitoneal lymph node dissection in clinical stage A non-seminomatous germ cell testis cancer: Review of the Indiana University experience 1965–1989. Br J Urol 71: 326–335.PubMedGoogle Scholar
  64. [64]
    Donohue JP, Fox EP, Williams SD, et al. (1994a) Persistent cancer in postchemotherapy retroperitoneal lymph-node dissection: Outcome analysis. World J Urol 12: 190–195.PubMedGoogle Scholar
  65. [65]
    Donohue JP, Thornhill JA, Foster RS, et al. (1994b) Stage I nonseminomatous germcell testicular cancer — Management options and risk-benefit considerations. World J Urol 12: 170–176.PubMedGoogle Scholar
  66. [66]
    Droz JP, Kramar A, Pico JL (1993a) Prediction of long-term response after high-dose chemotherapy with autologous bone marrow transplantation in the salvage treatment of non-seminomatous germ cell tumours. Eur J Cancer 29A: 818–821.PubMedGoogle Scholar
  67. [67]
    Droz JP, van Oosterom AT (1993b) Treatment options in clinical stage I non-seminomatous germ cell tumours of the testis: A wager on the future? A review. Eur J Cancer 29A: 1038–1044.PubMedGoogle Scholar
  68. [68]
    Duchesne GM, Stenning SP, Aass N, et al. (1997) Radiotherapy after chemotherapy for metastatic seminoma — A diminishing role. MRC Testicular Tumour Working Party. Eur J Cancer 33: 829–835.PubMedGoogle Scholar
  69. [69]
    Dunn TA, Grunwald V, Bokemeyer C, et al. (1997) Pre-clinical activity of taxol in nonseminomatous germ cell tumor cell lines and nude mouse xenografts. Invest New Drugs 15:91–98.PubMedGoogle Scholar
  70. [70]
    Einhorn L, Williams S, Mandelbaum I, et al. (1981) Surgical resection in disseminated testicular cancer following chemotherapeutic cytoreduction. Cancer 48: 904–908.PubMedGoogle Scholar
  71. [71]
    Einhorn LH, Stender MJ, Williams SD (1999) Phase II trial of gemcitabine in refractory germ cell tumors. J Clin Oncol. 17(2): 509–511.PubMedGoogle Scholar
  72. [72]
    Ellison M, Mostofi F, Flanigan R (1988) Treatment of the residual retroperitoneal mass after chemotherapy for advanced seminoma. J Urol 140: 618–620.PubMedGoogle Scholar
  73. [73]
    Farhat F, Culine S, Theodore C, et al. (1996) Cisplatin and ifosfamide with either vinblastine or etoposide as salvage therapy for refractory or relapsing germ cell tumor patients: The Institut Gustave Roussy experience. Cancer 77: 1193–1197.PubMedGoogle Scholar
  74. [74]
    Fizazi K, Ragan D, Bokemeyer C, et al. (1999) Viable malignant cells after primary chemotherapy for metastatic non-seminomatous germ-cell tumors (NSGCT): Results from an international study. Proc Am Soc Clin Oncol 18 (abstr.).Google Scholar
  75. [75]
    Fleming ID (ed) (1997) Testis. AJCC Cancer Staging Manual. 5th Ed. Lippincott-Raven, Philadelphia, S. 225–230.Google Scholar
  76. [76]
    Fossa SD, Borge L, Ass N, et al. (1987) The treatment of advanced metastatic seminoma. Experience in 55 cases. J Clin Oncol 5: 1071–1077.PubMedGoogle Scholar
  77. [77]
    Fossa S, Aass N, Kaalhus O (1989a) Radiotherapy for testicular seminoma stage I: Treatment results and long-term post-irradiation morbidity in 365 patients. Int J Radiat Oncol Biol Phys 16: 383–388.PubMedGoogle Scholar
  78. [78]
    Fossa SD, Ous S, Lien HH, et al. (1989b) Post-chemotherapy lymph node histology in radiologically normal patients with metastatic nonseminomatous testicular cancer. J Urol 141: 557–559.PubMedGoogle Scholar
  79. [79]
    Fossa SD, Droz JP, Stoter G, et al (1995) Cisplatin, vincristine and ifosphamide combination chemotherapy of metastatic seminoma: Results of EORTC trial 30874. EORTC GU Group. Br J Cancer 71: 619–624.PubMedGoogle Scholar
  80. [80]
    Fossa SD, Kaye SB, Mead GM, et al. (1998) Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. J Clin Oncol 16: 716–724.PubMedGoogle Scholar
  81. [81.
    Fossa SD, Stenning SP, Gerl A, et al. (1999) Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours. Br J Cancer 80(9): 1392–1399.PubMedGoogle Scholar
  82. [82]
    Fox E, Weathers T, Williams S, et al. (1993) Outcome analysis for patients with persistent nonteratomatous germ cell tumor in postchemotherapy retroperitoneal lymph node dissections. J Clin Oncol 11: 1294–1299.PubMedGoogle Scholar
  83. [83]
    Friedman NB (1987) The function of the primordial germ cell in extragonadal tissues. Int J Androl 10(1): 43–49.PubMedGoogle Scholar
  84. [84]
    Freedman LS, Parkinson MC, Jones WG, et al. (1987) Histopathology in the prediction of relapse of patients with stage I testicular teratoma treated by orchiectomy alone. Lancet 2(8554): 294 298.PubMedGoogle Scholar
  85. [85]
    Ganjoo KN, Chan RJ, Sharma M, et al. (1999) Positron emission tomography scans in the evaluation of postchemotherapy residual masses in patients with seminoma. J Clin Oncol 17(11): 3457–3460.PubMedGoogle Scholar
  86. [86]
    Gerl A, Clemm C, Schmeller N, et al. (1994) Sequential resection of residual abdominal and thoracic masses after chemotherapy for metastatic non-seminomatous germ cell tumours. Br J Cancer 70: 960–965.PubMedGoogle Scholar
  87. [87]
    Gerl A, Clemm C, Schmeller N, et al. (1995a) Outcome analysis after post-chemotherapy surgery in patients with non-seminomatous germ cell tumours. Ann Oncol 6: 483–488.PubMedGoogle Scholar
  88. [88]
    Gerl A, Clemm C, Schmeller N, et al. (1995b) Prognosis after salvage treatment for unselected male patients with germ cell tumours. Br J Cancer 72: 1026–1032.PubMedGoogle Scholar
  89. [89]
    Gietema JA, Sleijfer DTh, Willemse PHB, et al. (1992) Long-term follow-up of cardiovascular risk factors in patients given chemotherapy for disseminated nonseminoma tous testicular cancer. Ann Intern Med 116: 709–715.PubMedGoogle Scholar
  90. [90]
    Gregory C, Peckham M (1986) Results of radiotherapy for stage II testicular seminoma. Radiother Oncol 6: 285–292.PubMedGoogle Scholar
  91. [91]
    Hainsworth JD, Williams SD, Einhorn LH, et al. (1985) Successful treatment of resistant germinal neoplasms with VP-16 and cisplatin: Results of a Southeastern Cancer Study Group trial. J Clin Oncol 3: 666–671.PubMedGoogle Scholar
  92. [92]
    Harstrick A, Caspar J, Guba R, et al. (1989) Comparison of the antitumor activity of cisplatin, carboplatin and iproplatin against established human testicular cancer cell lines in vivo and in vitro. Cancer 63: 1079–1083.PubMedGoogle Scholar
  93. [93]
    Harstrick A, Schmoll HJ, Wilke H, et al. (1991) Cisplatin, etoposide and ifosfamide salvage therapy for refractory or relapsed germ cell carcinoma. J Clin Oncol 9: 1549–1555.PubMedGoogle Scholar
  94. [94]
    Harstrick A, Schleucher N, Andresen E, et al. (1999) Tandem high-dose chemotherapy with carboplatin, etoposide and cyclophosphamide followed by peripheral blood stem cell retransfusion in cisplatin refractory germ cell cancer patients. Proc Am Soc Clin Oncol 18: 327a (abstr. 1259).Google Scholar
  95. [95]
    Hartmann JT, Candelaria M, Kuczyk MA, et al. (1997a) Comparison of histological results from the resection of residual masses at different sites after chemotherapy for metastatic non-seminomatous germ cell tumours. Eur J Cancer 33: 843–847.PubMedGoogle Scholar
  96. [96]
    Hartmann JT, Schmoll H-J, Kuczyk MA, et al. (1997b) Postchemotherapy resections of residual masses from metastatic non-seminomatous testicular germ cell tumors. Ann Oncol 8: 531–538.PubMedGoogle Scholar
  97. [97]
    Hartmann JT, Kollmannsberger C, Kanz L, et al. (1999a) Platinum organ toxicity and possible prevention in patients with testicular cancer. Int J Cancer 83: 866–869.PubMedGoogle Scholar
  98. [98]
    Hartmann JT, Schmoll H-J, Albrecht C, et al. (1999b) Long-term effects on sexual functioning and fertility after treatment of testicular cancer. Br J Cancer 80: 801–807.PubMedGoogle Scholar
  99. [99]
    Hartmann JT, Kanz L, Bokemeyer C (1999c) Diagnosis and treatment of patients with testicular germ cell cancer Drugs 58(2): 257–281.PubMedGoogle Scholar
  100. [100]
    Hartmann JT, Kuczyk MA, Kollmannsberger C, et al. (1999d) Future prospects in the chemotherapy of metastatic nonseminomatous testicular germ-cell cancer. World J Urol 17(5): 324–333.PubMedGoogle Scholar
  101. [101]
    Hartmann JT, Fels LM, Franzke A, et al. (2000a) Comparative study of the acute nephrotoxicity from standard dose cisplatin ± ifosfamide and high-dose chemotherapy with carboplatin and ifosfamide. Anticancer Res 20: 1177–1182.PubMedGoogle Scholar
  102. [102]
    Hartmann JT, Fels LM, Knop S, et al. (2000b) A randomized trial comparing the nephrotoxicity of cisplatin/ifosfamide-based combination chemotherapy with or without amifostine in patients with solid tumors. Invest New Drugs 18: 281–289.PubMedGoogle Scholar
  103. [103]
    Hartmann JT, Knop S, Fels LM, et al. (2000c) The use of reduced doses of amifostine to ameliorate nephrotoxicity of cisplatin/ifosfamide-based chemotherapy in patients with solid tumors. Anti Cancer Drugs 11: 1–6.PubMedGoogle Scholar
  104. [104]
    Hartmann JT, Nichols CR, Droz JP, et al. (2000d) Extragonadal germ cell tumors (EGGCT) and hematological disorders: Incidence and outcome from an international database. J Natl Cancer Inst 92: 54–61.PubMedGoogle Scholar
  105. [105]
    Hartmann JT, Nichols CR, Droz JP, et al. (2000e) The relative risk of second nongerminal malignancies in patients with extragonadal germ cell tumors. Cancer 88(11): 2629–2635.PubMedGoogle Scholar
  106. [106]
    Hartmann JT, von Vangerow A, Fels LM, et al. (2001 a) A randomized trial of amifostine in patients with high dose VIC chemotherapy plus autologous blood stem cell transplantation. Br J Cancer (in press).Google Scholar
  107. [107]
    Hartmann JT, Schleucher N, Metzner B, et al. (2001b) Phase I/II study of sequential high dose VIP plus paclitaxel supported by PBSC in patients with ‘poor prognosis’ germ cell tumor (GCT). Proc Am Soc Clin Oncol (in press).Google Scholar
  108. [108]
    Hartmann JT, Nichols CR, Droz JP, et al. (2001c) Salvage chemotherapy for patients with relapsed nonseminomatous extragonadal germ cell tumors. J Clin Oncol (in press).Google Scholar
  109. [109]
    Hendry WF, A’Hern RP, Hetherington JW, et al. (1993) Para-aortic lymphadenectomy after chemotherapy for metastatic non-seminomatous germ cell tumours: Prognostic value and therapeutic benefit. Br J Urol 71: 208–213.PubMedGoogle Scholar
  110. [110]
    Hernes EH, Harstad K, Fossa SD (1992) Changing incidence and delay of testicular cancer in southern Norway (1981-1992). Eur Urology 30: 349–357.Google Scholar
  111. [111]
    Herr HW, Sheinfeld J, Puc HS, et al. (1997) Surgery for a post-chemotherapy residual mass in seminoma. J Urol 157: 860–862.PubMedGoogle Scholar
  112. [112]
    Horwich A, Dearnaley DP, A’Hern R, et al. (1992) The activity of single-agent carboplatin in advanced seminoma. Eur J Cancer 28A: 1307–1310.PubMedGoogle Scholar
  113. [113]
    Horwich A, Paluchowska B, Normann A, et al. (1997a) Residual mass following chemotherapy of seminoma. Ann Oncol 8: 37–40.PubMedGoogle Scholar
  114. [114]
    Horwich A, Sleijfer DT, Fossa SD, et al. (1997b) Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: A Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer trial. J Clin Oncol 15: 1844–1852.PubMedGoogle Scholar
  115. [115]
    Horwich A, Oliver RTD, Fossa SD, et al. (2000) A MRC randomised trial of single agent carboplatin versus etoposide and cisplatin for advanced metastatic seminoma. BrJ of Cancer 83(12): 1623–1629.Google Scholar
  116. [116]
    Jacobsen G, Henriksen OB, von der Maase H (1981) Carcinoma in situ of testicular tissue adjacent to malignant germ-cell tumors: A study of 105 cases. Cancer 47(11): 2660–2662.PubMedGoogle Scholar
  117. [117]
    Jones DM, Amato LC, Pagliari R, et al. (1997) Carboplatin (CBDCA) and cyclo-phosphamide (CTX) and delayed consolidation in advanced seminoma. Proc Am Soc Clin Oncol 16: 323a (abstr. 1149).Google Scholar
  118. [118]
    Josefsen D, Ous S, Hoie J, et al. (1993) Salvage treatment in male patients with germ cell tumours. Br J Cancer 67: 568–572.PubMedGoogle Scholar
  119. [119]
    Kaye B, Mead GM, Fossa S, et al. (1998) Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor prognosis metastatic nonseminomatous germ cell tumor: A randomized medical research council/European organization for research and treatment of cancer study. J Clin Oncol 16:692–701.PubMedGoogle Scholar
  120. [120]
    Kollmannsberger C, Beyer J, Droz J-P, et al. (1998) Secondary leukemia following high cumulative doses of stoposide in patients treated for advanced germ cell tumors. J Clin Oncol 16: 3386–3391.PubMedGoogle Scholar
  121. [121]
    Lampe H, Dearnaley DP, Price A, et al. (1995) High-dose carboplatin and etoposide for salvage chemotherapy of germ cell tumours. Eur J Cancer 31 A: 717–723.Google Scholar
  122. [122]
    Lampe H, Horwich A, Norman A, et al. (1997) Fertility after chemotherapy for testicular germ cell cancers. J Clin Oncol 15: 239–245.PubMedGoogle Scholar
  123. [123]
    Ledermann JA, Holden L, Newlands ES, et al. (1994) The long-term outcome of patients who relapse after chemotherapy for non-seminomatous germ cell tumours. Br J Urol 74: 225–230.PubMedGoogle Scholar
  124. [124]
    Leibovitch I, Foster RS, Kopecky KK, et al. (1998) Identification of clinical stage a nonseminomatous testis cancer patients at extremely low risk for metastatic disease: A combined approach using quantitive immunohistochemical, histopathologic, and radiologic assessment. J Clin Oncol 16: 261–268.PubMedGoogle Scholar
  125. [125]
    Leitner SP, Bosl GJ, Bajorunas D (1986) Gonadal dysfunction in patients treated for metastatic germ-cell tumors. J Clin Oncol 4: 1500–1505.PubMedGoogle Scholar
  126. [126]
    Linkesch W, Krainer M, Wagner A (1992) Phase I/II trial of ultrahigh carboplatin, etoposide, cyclophosphamide with ABMT in refractory or relapsed non-seminomatous germ cell tumors (NSGCT). Proc Am Soc Clin Oncol 11: 196 (abstr. 600).Google Scholar
  127. [127]
    Loehrer PJ Sr, Johnson D, Elson P, et al. (1995) Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: An Eastern Cooperative Oncology Group trial. J Clin Oncol 13: 470–476.PubMedGoogle Scholar
  128. [128]
    Loehrer PJ, Birch R, Williams SD, et al. (1987) Chemotherapy of metastatic seminoma: The Southeastern Cancer Study Group Experience. J Clin Oncol 5: 1212–1220.PubMedGoogle Scholar
  129. [129]
    Loehrer PJ, Gonin R, Nichols CR, et al. (1998) Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. J Clin Oncol 16: 2500–2504.PubMedGoogle Scholar
  130. [130]
    Loehrer PJ, Lauer R, Roth BJ, et al. (1988) Salvage therapy in recurrent germ cell cancer: Ifosfamide and cisplatin plus either vinblastine or etoposide. Ann Intern Med 109: 540–546.PubMedGoogle Scholar
  131. [131]
    Logothetis CJ, Samuels ML, Ogden SL, et al. (1987) Cyclophosphamide and sequential cisplatin for advanced seminoma: Long-term follow up in 52 patients. J Urol 138: 789–794.PubMedGoogle Scholar
  132. [132]
    Logothetis CJ, Samuels ML, Trindade A, et al. (1982) The growing teratoma syndrome. Cancer 50: 1629–1635.PubMedGoogle Scholar
  133. [133]
    Mandelbaum I, Yaw PB, Einhorn LH, et al. (1983) The importance of one-stage median sternotomy and retroperitoneal node dissection in disseminated testicular cancer. Ann Thorac Surg 36: 524–528.PubMedGoogle Scholar
  134. [134]
    Manivel J, Jessurun J, Wick M, et al. (1987) Placental alkaline phosphatase immunoreactivity in testicular germ-cell neoplasms. Am J Surg Pathol 11: 21–29.PubMedGoogle Scholar
  135. [135]
    Margolin K, Doroshow JH, Ahn C, et al. (1996) Treatment of germ cell cancer with two cycles of high-dose ifosfamide, carboplatin, and etoposide with autologous stemcell support. J Clin Oncol 14: 2631–2637.PubMedGoogle Scholar
  136. [136]
    McCaffrey JA, Mazumdar M, Bajorin DF, et al. (1997) Ifosfamide-and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors: Response and survival. J Clin Oncol 15: 2559–2563.PubMedGoogle Scholar
  137. [137]
    McGuire WP, Rowinsky EK, Rosenshein NB, et al. (1989) Taxol: A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 111: 273–279.PubMedGoogle Scholar
  138. [138]
    McLeod DG, Weiss RB, Stablein DM, et al. (1991) Staging relationships and outcome in early stage testicular cancer: A report from the Testicular Cancer Inter-group Study. J Urol 145: 1178–1183.PubMedGoogle Scholar
  139. [139]
    Mead GM, Stenning SP, Cook P, et al. (1997) International germ cell consensus classification: A prognostic factor-erased staging system for metastatic germ cell cancers. J Clin Oncol 15: 594–603.Google Scholar
  140. [140]
    Mencel PJ, Motzer RJ, Mazumdar M, et al. (1994) Advanced seminoma: Treatment results, survival, and prognostic factors in 142 patients. J Clin Oncol 12: 120–126.PubMedGoogle Scholar
  141. [141]
    Molenaar WM, Oosterhuis JW, Meiring A, et al. (1986) Histology and DNA contents of a secondary malignancy arising in a mature residual lesion six years after chemotherapy for a disseminated nonseminomatous testicular tumor. Cancer 58: 264–268.PubMedGoogle Scholar
  142. [142]
    Mostert MMC, van de Pol M, Olde-Weghuis D, et al. (1996) Comparative genomic hybridization of germ cell tumors of the adult testis: Confirmation of karyotypic findings and identification of a 12p-amplicon. Cancer Genet Cytogenet 89: 146–152.PubMedGoogle Scholar
  143. [143]
    Mostofi FK, Seterhenn IA (1998) WHO Classification of Testicular Cancer, 2nd Ed. Springer, Berlin.Google Scholar
  144. [144]
    Motzer RJ, Bajorin DF, Schwartz LH, et al. (1994) Phase II trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumors. J Clin Oncol 12: 2277–2283.PubMedGoogle Scholar
  145. [145]
    Motzer RJ, Cooper K, Geller NL, et al. (1990) The role of ifosfamide plus cisplatinbased chemotherapy as salvage therapy for patients with refractory germ cell tumors. Cancer 66: 2476–2481.PubMedGoogle Scholar
  146. [146]
    Motzer RJ, Gulati SC, Crown JP, et al. (1992) High-dose chemotherapy and autologous bone marrow rescue for patients with refractory germ cell tumors. Cancer 69: 550–556.PubMedGoogle Scholar
  147. [147]
    Motzer RJ, Mazumdar M, Subhash CG, et al. (1993) Phase II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J Natl Cancer Inst 85: 1828–1835.PubMedGoogle Scholar
  148. [148]
    Motzer RJ, Sheinfeld J, Mazumdar M, et al. (1995) Etoposide and cisplatin adjuvant therapy for patients with pathologic stage II germ cell tumors. J Clin Oncol 13: 2700–2704.PubMedGoogle Scholar
  149. [149]
    Motzer RJ, Mazumdar M, Bosl GJ, et al. (1996) High-dose carboplatin, etoposide, and cyclophosphamide for patients with refractory germ cell tumors: Treatment results and prognostic factors for survival and toxicity. J Clin Oncol 14: 1098–1105.PubMedGoogle Scholar
  150. [150]
    Motzer RJ, Mazumdar M, Sheinfeld J, et al. (2000) Sequential dose-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patients. J Clin Oncol 18(6): 1173–1180.PubMedGoogle Scholar
  151. [151]
    Mulder POM, de Vries EG, Koops HS, et al. (1988) Chemotherapy with maximally tolerable doses of VP-16-123 and cyclophosphamide followed by autologous bone marrow transplantation for the treatment of relapsed or refractory germ cell tumors. Eur J Cancer Clin Oncol 24: 675–679.PubMedGoogle Scholar
  152. [152]
    Mulders PFA, Oosterhoff GON, Boetse C, et al. (1990) The importance of prognostic factors in the individual treatment of patients with disseminated germ cell tumours. Br J Urol 66: 425–429.PubMedGoogle Scholar
  153. [153]
    Murphy B, Breeden E, Donohue J, et al. (1993) Surgical salvage of chemorefractory germ cell tumors. J Clin Oncol 11: 324–329.PubMedGoogle Scholar
  154. [154]
    Nichols CR, Tricot G, Williams S, et al. (1989) Dose-intensive chemotherapy in refractory germ cell cancer: A phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation. J Clin Oncol 7: 932–939.PubMedGoogle Scholar
  155. [155]
    Nichols CR, Roth BJ, Heerema N, et al. (1990) Hematologic neoplasia associated with primary mediastinal germ-cell tumors. N Engl J Med 322(20): 1425–1429.PubMedGoogle Scholar
  156. [156]
    Nichols CR, Williams SD, Loehrer PJ, et al. (1991) Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: A Southeastern Cancer Study Group and Southwest Oncology Group protocol. J Clin Oncol 7: 1163–1172.Google Scholar
  157. [157]
    Nichols CR, Breeden ES, Loehrer PJ (1993) Secondary leukemia associated with a conventional dose of etoposide: Review of serial germ cell tumor protocols. J Natl Cancer Inst 85: 36–40.PubMedGoogle Scholar
  158. [158]
    Nichols CR, Roth BJ, Loehrer PJ, et al. (1994) Salvage chemotherapy for recurrent germ cell cancer. Sem Oncol 5(Suppl. 12): 102–108.Google Scholar
  159. [159]
    Nichols CR, Catalano PJ, Crawford ED, et al. (1998) Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: An Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B study. J Clin Oncol 16: 1287–1293.PubMedGoogle Scholar
  160. [160]
    Osanto S, Bukman A, Van Hoek F, et al. (1992) Long-term effects of chemotherapy in patients with testicular cancer. J Clin Oncol 10: 574–579.PubMedGoogle Scholar
  161. [161]
    Osterlind A (1986) Diverging trends in incidence and mortality of testicular cancer in Denmark, 1943-1982. Br J Cancer 53: 501–505.PubMedGoogle Scholar
  162. [162]
    Ozols RF, Ihde DC, Linehan WM, et al. (1988) A randomized trial of standard chemo-therapy versus a high-dose chemotherapy regimen in the treatment of poor prognosis nonseminomatous germ-cell tumors. J Clin Oncol 6: 1031–1040.PubMedGoogle Scholar
  163. [163]
    Partyka S, Hutchinson L, Amato R (1996) Preliminary results of taxol/cisplatin chemotherapy in patients with refractory or relapsed nonseminomatous germ cell tumor. Proc Am Assoc Cancer Res 37: 169 (abstr. 1161).Google Scholar
  164. [164]
    Peckham MJ, Barrett A, Husband JE, et al. (1982) Orchiectomy alone in testicular stage I nonseminomatous germ cell tumors. Lancet 2(8300): 678–680.PubMedGoogle Scholar
  165. [165]
    Pedersen-Bjergaard J, Daugaard G, Hansen ST, et al. (1991) Increased risk of myelodysplasia and leukemia after etoposide, cisplatin, and bleomycin for germ-cell tumors. Lancet 338(8763): 359–363.PubMedGoogle Scholar
  166. [166]
    Pizzocaro G, Pasi M, Salvioni R, et al. (1985) Cisplatin and etoposide salvage therapy and resection of the residual tumor in pretreated germ cell testicular cancer. Cancer 56:2399–2403.PubMedGoogle Scholar
  167. [167]
    Pizzocaro G, Salvioni R, Piva L, et al. (1986) Cisplatin combination chemotherapy in advanced seminoma. Cancer 58: 1625–1629.PubMedGoogle Scholar
  168. [168]
    Pizzocaro G (1996) Rationale for lymphadenectomy in stage I nonseminoma: In: Horwich A (ed) Testicular Cancer, 2nd Ed. Chapman and Hall, London, S. 193–200.Google Scholar
  169. [169]
    Pont J, Albrecht W, Postner G, et al. (1996) Adjuvant chemotherapy for high-risk clinical stage I nonseminomatous testicular germ cell cancer: Long-term results of a prospective trial. J Clin Oncol 14: 441–448.PubMedGoogle Scholar
  170. [170]
    Pryor JP, Cameron KM, Chilton CP, et al. (1983) Carcinoma in situ in testicular biopsies from men presenting with infertility. Br J Urol 55: 780–784.PubMedGoogle Scholar
  171. [171]
    Puc HS, Heelan R, Mazumdan M, et al. (1996) Management of residual mass in advanced seminoma: Results and recommendations from the Memorial Sloan Kettering Cancer Center. J Clin Oncol 14: 454–460.PubMedGoogle Scholar
  172. [172]
    Qvist HL, Fossa SD, Ous S, et al. (1991) Post-chemotherapy tumour residuals in patients with advanced nonseminomatous testicular cancer. Is it necessary to resect all residual masses? J Urol 145: 300–303.PubMedGoogle Scholar
  173. [173]
    Raghavan D, Vogelzang NJ, Bosl GJ, et al. (1982) Tumor classification and size in germ-cell testicular cancer: Influence on the occurrence of metastases. Cancer 50: 1591–1595.PubMedGoogle Scholar
  174. [174]
    Rick O, Bokemeyer C, Beyer J, et al. (2001) Salvage treatment with paclitaxel, ifosfamide, and cisplatin plus high-dose carboplatin, etoposide, and thiotepa followed by autologous stem-cell rescue in patients with relapsed or refractory germ cell cancer. J Clin Oncol 19: 81–88.PubMedGoogle Scholar
  175. [175]
    Rodenhuis S, de Wit R, de Mulder PMH, et al. (1999) A prospective trial of repeated high-dose chemotherapy in relapsing germ cell cancer. Proc Am Soc Clin Oncol 18: 310a (abstr. 1190).Google Scholar
  176. [176]
    Rodriguez E, Mathew S, Reuter V, et al. (1992) Cytogenetic analysis of 124 prospectively ascertained male germ cell tumors. Cancer Res 52: 2285–2291.PubMedGoogle Scholar
  177. [177]
    Rosti G, Albertazzi L, Salioni R, et al. (1992) High-dose chemotherapy supported with autologous bone marrow transplantation (ABMT) in germ cell tumors: A phase two study. Ann Oncol 3: 809–812.PubMedGoogle Scholar
  178. [178]
    Roth BJ, Einhorn LH, Greist A (1988) Long-term complications of cisplatin-based chemotherapy for testis cancer. Sem Oncol 15: 345–350.Google Scholar
  179. [179]
    Rowinsky EK, Gilbert MR, McGuire WP, et al. (1991) Sequences of taxol and cisplatin: A phase I and pharmacologic study. J Clin Oncol 9: 1692–1703.PubMedGoogle Scholar
  180. [180]
    Sandler AB, Christou A, Fox S, et al. (1998) A phase II trial of paclitaxel in refractory germ cell neoplasms. Cancer 82: 1381–1386.PubMedGoogle Scholar
  181. [181]
    Satge D, Sasco AJ, Cure H, et al. (1997) An excess of testicular germ cell tumors in Down’s syndrome. Cancer 80: 929–935.PubMedGoogle Scholar
  182. [182]
    Saxman SB, Finch D, Gonin R, et al. (1998) Long-term follow-up of a phase III study of three versus four cycles of bleomycin, etoposide, and cisplatin in favorable-prognosis germ-cell tumors: The Indiana University experience. J Clin Oncol 15: 702–706.Google Scholar
  183. [183]
    Schmoll HJ, Harstrick A, Bokemeyer C, et al. (1993) Single-agent carboplatinum for advanced seminoma. A phase II study. Cancer 72: 237–242.Google Scholar
  184. [184]
    Schmoll HJ (1989) The role of ifosfamide in testicular cancer. Semin Oncol 16 (Suppl 3): 82–95.PubMedGoogle Scholar
  185. [185]
    Sesterhenn IA, Weiss RB, Mostofi FK, et al. (1992) Prognosis and other clinical correlates of pathologic review in stage I and II testicular carcinoma: A report from the Testicular Cancer Intergroup Study. J Clin Oncol 10(1): 69–78.PubMedGoogle Scholar
  186. [186]
    Siegert W, Beyer J, Strohscheer I, et al. (1994) High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: A phase I/II study. The German Testicular Cancer Cooperative Study Group. J Clin Oncol 12: 1223–1231.PubMedGoogle Scholar
  187. [187]
    Sleijfer S, Willemse PHB, de Vries EGE, et al. (1996) Treatment of advanced seminoma with cyclophosphamide, vincristine and carboplatin on an outpatient basis. Br J Cancer 74: 947–950.PubMedGoogle Scholar
  188. [188]
    Stephens WS, Gonin R, Hutchins GD, et al. (1996) Positron emission tomography evaluation of residual radiographic abnormalities in postchemotherapy germ cell tumour patients. J Clin Oncol 14: 1637–1641.PubMedGoogle Scholar
  189. [189]
    Steyerberg EW, Keizer HJ, Zwartendijk J, et al. (1993) Prognosis after resection of residual masses following chemotherapy for metastatic nonseminomatous testicular cancer: A multivariate analysis. Br J Cancer 68: 195–200.PubMedGoogle Scholar
  190. [190]
    Steyerberg EW, Keizer HJ, Stoter G, et al. (1994) Predictors of residual mass histology following chemotherapy for metastatic non-seminomatous testicular cancer: A quantitative overview of 996 resections. Eur J Cancer 30: 1231–1239.Google Scholar
  191. [191]
    Steyerberg EW, Keizer HJ, Fossa SD, et al. (1995) Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumor: Multivariate analysis of individual patient data from six study groups. J Clin Oncol 13: 1177–1187.PubMedGoogle Scholar
  192. [192]
    Steyerberg EW, Gerl A, Fossa SD, et al. (1998) Validity of predictions of residual retroperitoneal mass histology in nonseminomatous testicular cancer. J Clin Oncol 16:269–274.PubMedGoogle Scholar
  193. [193]
    Stone J, Cruickshank D, Sandeman T, et al. (1991) Trebling of the incidence of testicular cancer in Victoria, Australia (1950-1985). Cancer 68: 211–219.PubMedGoogle Scholar
  194. [194]
    Tait D, Peckham MJ, Hendry WF, et al. (1984) Post-chemotherapy surgery in advanced non-seminomatous germ-cell testicular tumours: The significance of histology with particular reference to differentiated (mature) teratoma. Br J Cancer 50: 601–609.PubMedGoogle Scholar
  195. [195]
    The Italian Group for Antiemetic Research (1995) Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer. N Engl J Med 332: 1–5.Google Scholar
  196. [196]
    Tiffany P, Morse MJ, Bosl G, et al. (1986) Sequential excision of residual thoracic and retroperitoneal masses after chemotherapy for stage III germ cell tumours. Cancer 57: 978–983.PubMedGoogle Scholar
  197. [197]
    Toner GC, Panicek DM, Heelan RT, et al. (1990) Adjunctive surgery after chemotherapy for nonseminomatous germ cell tumors: recommendations for patient selection. J Clin Oncol 8: 1683–1694.PubMedGoogle Scholar
  198. [198]
    Travis LB, Curtis RE, Storm H, et al. (1997) Risk of second malignant neoplasms among long-term survivors of testicular cancer. J Natl Cancer Inst 89: 1429–1439.PubMedGoogle Scholar
  199. [199]
    van Leeuwen F, Stiggelbout A, van den Belt-Dusebout A, et al. (1993) Second cancer risk following testicular cancer: A follow up study of 1,909 patients. J Clin Oncol 11:415–424.PubMedGoogle Scholar
  200. [200]
    Vogelzang NJ, Bosl GJ, Johnson K (1981) Raynaud’s phenomenon: A common toxicity after combination chemotherapy for testicular cancer. Ann Intern Med 95: 288–292.PubMedGoogle Scholar
  201. [201]
    Vogelzang NJ, Torkelson JL, Kennedy BJ (1985) Hypomagnesemia, renal dysfunction, and Raynaud’s phenomenon in patients treated with cisplatin, vinblastine, and bleomycin. Cancer 56: 2765–2770.PubMedGoogle Scholar
  202. [202]
    Vos A, Oosterhuis W, de Jong B, et al. (1990) Cytogenetics of carcinoma in situ of the testis. Cancer Genet Cytogenet 46: 75–81.PubMedGoogle Scholar
  203. [203]
    Warde P, von der Maase H, Horwich A, et al. (1998) Stage I testicular seminoma: Results of adjuvant irradiation and surveillance. Proc Am Soc Clin Oncol 17: 309a (abstr. 1188).Google Scholar
  204. [204]
    Weijl NI, Rutten MFJ, Zwinderman AH, et al. (2000) Thromboembolic events during chemotherapy for germ cell cancer: A cohort study and review of the literature. J Clin Oncol 18(10): 2169–2178.PubMedGoogle Scholar
  205. [205]
    Willan BD, McGowan DG (1985) Seminoma of the testis: A 22-year experience with radiation therapy. Int J Radiat Oncol Biol Phys 11: 1769–1775.PubMedGoogle Scholar
  206. [206]
    Williams SD, Birch R, Einhorn LH, et al. (1987a) Treatment of disseminated germcell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 316: 1435–1440.PubMedGoogle Scholar
  207. [207]
    Williams SD, Stablein DM, Einhorn LH, et al. (1987b) Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer. N Engl J Med 317: 1433–1438.PubMedGoogle Scholar
  208. [208]
    Wolff SN, Johnson DH, Hainsworth JD, et al. (1984) High dose VP-16-213 monotherapy for refractory germinal malignancies. A phase II study. J Clin Oncol 4: 271–274.Google Scholar
  209. [209]
    Wood D, Herr H, Motzer R, et al. (1992) Surgical resection of solitary metastases after chemotherapy in patients with nonseminomatous germ cell tumors and elevated serum tumor markers. Cancer 70: 2354–2357.PubMedGoogle Scholar
  210. [210]
    Wozniak AJ, Samson MK, Shah NT, et al. (1991) A randomized trial of cisplatin, vinblastine, and bleomycin versus vinblastine, cisplatin, and etoposide in the treatment of advanced germ cell tumors of the testis: A Southwest Oncology Group study. J Clin Oncol 9: 70–76.PubMedGoogle Scholar
  211. [211]
    Xiao H, Mazumdar M, Bajorin DF, et al. (1997) Long-term follow-up of patients with good-risk germ cell tumors treated with etoposide and cisplatin. J Clin Oncol 15: 2553–2558.PubMedGoogle Scholar
  212. [212]
    Zagars GK, Babaian RJ (1987) Stage I testicular seminoma: Rationale for postorchidectomy radiation therapy. Int J Radiat Oncol Biol Phys 13: 155–162.PubMedGoogle Scholar

Copyright information

© Springer-Verlag Wien 2001

Authors and Affiliations

  • Jörg Thomas Hartmann
    • 1
  • Markus Kuczyk
  • Carsten Bokemeyer
  1. 1.Medizinische Klinik II, Universitätsklinikum TübingenEberhard-Karls-UniversitätTübingenDeutschland

Personalised recommendations